TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06088511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health System with nutritional advice
Description: A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building.
Study: NCT05501743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of microfat and PRP
Description: The treatment by intra-articular injection of autologous microfat and PRP will be performed during a half-day outpatient stay in the hand and limb repair surgery department at the Hôpital de la Timone. The total duration of the procedure is approximately 4 hours and includes 2 surgical times performed in the operating room and an intermediate waiting time for the patient in an outpatient room during the preparation of the experimental products.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total denervation of the wrist
Description: The surgical treatment by total denervation of the wrist will be performed during a one-day outpatient stay in the hand and limb surgery department at the Hôpital de la Timone. It will be performed under loco-regional anesthesia by axillary plexus block.
Study: NCT06012110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: While participants are supine with a pillow placed below the knees for comfort, one 30-minute transcutaneous electrical stimulation session will be performed at a frequency of 50 Hz, pulse width of 400 microseconds and individualized amplitude will be completed.
Study: NCT04543188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
Study: NCT04794465

Intervention type: DIAGNOSTIC_TEST
Intervention: Colorectal cancer screening
Description: Patients with IBP diagnosed during the colorectal cancer screening
Study: NCT05624814

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
Study: NCT05687019

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Ialuril® Prefill
Description: 5 injections of Ialuril® Prefill on D0 or D1, D7, D14, D21 and D28 after Holmium laser surgery for prostate adenoma
Study: NCT05251038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Intervention instruction outlined in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan (nal-IRI)
Description: Intervention instruction outlined in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil (5FU)
Description: Per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: Per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Description: Per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Per standard of care
Study: NCT05683015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient questionnaires
Description: The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
Study: NCT05543941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilute Betadine
Description: The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
Study: NCT05546671

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand grip strength measurement
Description: Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg

Intervention type: DIAGNOSTIC_TEST
Intervention: Hand grip strength measurement
Description: Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg
Study: NCT05124379

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemoclin Gel
Description: Non sterile gel for intra-rectal use
Study: NCT06071442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemircopan
Description: Participants will receive oral tablets of Vemircopan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemircopan
Description: Participants will receive oral tablets of Vemircopan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemircopan
Description: Participants will receive oral tablets of Vemircopan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive oral coated tablets of Rosuvastatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive oral film-coated tablets of Metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel / Ethinyl Estradiol
Description: Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Participants will receive oral chewable tablets of Carbamazepine.
Study: NCT05533931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistive Breathing Training group
Description: The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory hold technique
Description: With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
Study: NCT05424679

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning Intervention
Description: The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Description: Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
Study: NCT06377618

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resistance Training and Core Strengthening Exercises Group
Description: The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation
Description: Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
Study: NCT04650594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MUTARS® modular reconstruction prostheses
Description: Patients with MUTARS® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year
Study: NCT03678467

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EB-CMF
Description: Autologous, anatomically shaped bone graft
Study: NCT05624814

Intervention type: OTHER
Intervention: Standard therapies
Description: Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
Study: NCT05236868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
Study: NCT05134363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride 0.5 mic/kg bolus
Description: comparison between two bolus doses of dexmedetomidine with a placebo group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride 0.75 mic/kg bolus
Description: comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equal volume of normal saline
Study: NCT03615547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene Citrate
Description: After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
Study: NCT05515289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
Study: NCT04927936

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination once with Janssen vaccine (only priming)
Description: Vaccination (priming) with janssen vaccine. There is no boosting.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).
Description: Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).
Description: Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
Study: NCT05701436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, Leucovorin, fluorouracil
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Leucovorin, fluorouracil
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin, Raltitrexed
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin, Raltitrexed
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study: NCT05597332

Intervention type: OTHER
Group type: OTHER
Intervention: Care bundle for AKI
Description: To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
Study: NCT05215730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedCu wound dressings with copper oxide (COD)
Description: Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedCu wound dressings with copper oxide (COD)
Description: Patients whose foot wound is indicated for VAC treatment will be randomized to either treatment arm after signing informed consent.
Study: NCT05400421

Intervention type: DEVICE
Intervention: System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure
Description: Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.

Intervention type: DEVICE
Intervention: System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure
Description: Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
Study: NCT04927936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).
Description: Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
Study: NCT06346925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine Tablets
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine Tablets
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.
Study: NCT05187520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA)
Description: Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldebain®
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT06495463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days.
Study: NCT06130605

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT05396755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC)
Description: invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)